Monday Morning Session Preview: Instrumentation: New Developments in High Resolution and Mass Accuracy in Honor of Alan Marshall's 70th Birthday
This Monday morning session will be presided over by Patrick Limbach of the University of Cincinnati and will be held at 8:30?10:30 a.m. in Room 307-308.
This Monday morning session will be presided over by Patrick Limbach of the University of Cincinnati and will be held at 8:30–10:30 a.m. in Room 307-308.
The first presentation in the session will be given by Lutz Schweikhard of the University of Greifswald (Greifswald, Germany) and is titled “Precision Mass Spectrometry on Short-Lived Nuclides: New Methods and Results.”
The next talk, to be delivered by Eugene Nikolaev of the Institute for Energy Problems of Chemical Physics (Moscow, Russia) is titled “Further Characterization and Applications of Dynamically Harmonized FT ICR Cell.”
Juan Wei of the University of the University of Warwick (Coventry, UK) will present the next talk, “Pushing the Limits: Using Isotopic Fine Structure Mass Spectrometry to Assist the Understanding of 17O Labelled Peptides in NMR.”
The fourth presentation in the session, “Unexplored Reserves of Resolution in Fourier Transform Mass Spectrometry,” will be delivered by Anton N. Kozhinov of Ecole Polytechnique Fédérale de Lausanne (Lausanne, Switzerland).
The penultimate presentation will be given by Jeffrey Spraggins of Vanderbilt University (Nashville, Tennessee) and is titled “High-Field FTICR MS for Imaging Applications: Combining Ultra-High Resolving Power and Mass Accuracy with High Spatial Resolution and Throughput.”
Finally, Nathan Kaiser of the National High Magnetic Field Laboratory (Tallahassee, Florida) will present “Development of an FT-ICR Mass Spectrometer in Preparation for 21 Tesla.”
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
